PROFUSA Debt/Equity Ratio 2022-2021 | PFSA

PROFUSA debt/equity ratio from 2022 to 2021. Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

PROFUSA Debt/Equity Ratio 2022-2021 | PFSA

PROFUSA debt/equity ratio from 2022 to 2021. Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.
Related Stocks
Company NameMarket
Cap
Veeva Systems (VEEV)$47.8B
Hims & Hers Health (HIMS)$13.1B
Doximity (DOCS)$11.5B
Tempus AI (TEM)$10.7B
IRhythm Technologies (IRTC)$4.4B
Inspire Medical Systems (INSP)$3.9B
Hinge Health (HNGE)$3.5B
Privia Health (PRVA)$2.4B
10x Genomics (TXG)$1.8B
Schrodinger (SDGR)$1.6B
Phreesia (PHR)$1.6B
Azenta (AZTA)$1.6B
Enovis (ENOV)$1.6B
Clover Health Investments (CLOV)$1.5B
Omnicell (OMCL)$1.4B
Evolent Health (EVH)$1.1B
Claritev (CTEV)$664M
Fulgent Genetics (FLGT)$549M
Standard BioTools (LAB)$539M
Veradigm (MDRX)$507M
Butterfly Network (BFLY)$480M
Talkspace (TALK)$428M
TruBridge (TBRG)$347M
Outset Medical (OM)$320M
Health Catalyst (HCAT)$285M
Nyxoah SA (NYXH)$244M
SOPHiA GENETICS SA (SOPH)$224M
CapsoVision (CV)$202M
Zepp Health (ZEPP)$199M
KORU Medical Systems (KRMD)$157M